Treatment of Hepatitis C with Direct Action Antivirals in Brazzaville, Congo

The drug treatment of hepatitis C represents a great therapeutic advance in favor of the elimination of the virus. The present study assessed the efficacy of treatment regimens involving direct action antivirals (DAAs), given to patients with chronic hepatitis C, attended at a referral hospital of infectology, central Brazil. This is a descriptive and cross - sectional study, based on the electronic database of the outpatient pharmacy, that evaluated the characteristics of patients and drug regimens involving DAA, from November 2015 to June 2017. Among 717 patients enrolled in this study, most of them had advanced liver fibrosis, were treatment naïve and HCV genotype 1 infected almost 80% of participants. A high efficacy of HCV treatment was achieved with 97% (95% CI: 94.9-98.2%) of SVR among the 431 patients who presented the results of viral load tests (HCV-RNA) at 12 weeks post-treatment. Patients infected with genotype 3 and who were cirrhotic had a lower SVR rate (87%). Treatment efficacy was not associated with age or sex among participants. The results of this study corroborate the findings in literature that showed a high efficacy of DAAs in the treatment of chronic hepatitis C, implemented through the clinical protocol and therapeutic guidelines for hepatitis C of the Ministry of Health in 2015. Many challenges must be overcome in order to combating viral hepatitis. In this context, the efficacy of HCV treatment it is an important issue to achieve the HCV elimination as a public health threat

Download Full-text

Clinical, Epidemiological, and Geospatial Characteristics of Patients Infected with Hepatitis C Virus Treated with Second-Generation Direct-Action Antivirals in a Reference Center in a Mesoregion of São Paulo State, Brazil

Microorganisms ◽

10.3390/microorganisms8101575 ◽

2020 ◽

Vol 8 (10) ◽

pp. 1575

Author(s):

Danilo Zangirolami Pena ◽

Murilo Fernandes Anadão ◽

Edilson Ferreira Flores ◽

Mayara Namimatsu Okada ◽

Alexandre Martins Portelinha Filho ◽

...

Keyword(s):

Public Health ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Health System ◽

Second Generation ◽

Direct Action ◽

Sao Paulo ◽

Reference Center ◽

Paulo State ◽

São Paulo State

Hepatitis virus infection is a major public health problem worldwide. Currently, Brazil has almost 700,000 cases. The Brazilian Unified Health System (SUS) provides therapeutic regimens for people infected with hepatitis C virus (HCV). We determined the clinical, laboratory, epidemiologic, and geospatial characteristics of patients infected with HCV treated with second-generation direct-action antivirals (DAAs) in a hospital reference center in São Paulo state, Brazil, using data from file records. A map was constructed using a geographic information system. From 2015 to 2018, 197 individuals received second-generation DAAs (mean age, 57.68 ± 1.36 years; interquartile range, 56.22–59.14 years; 58.9% male; 41.1% female). Genotypes 1a and 1b accounted for 75.7% of cases and the prevalent therapeutic regimen was sofosbuvir/simeprevir. Sustained viral response accounted for 98.9% and the METAVIR score F3/F4 for 50.8%. Increased alanine transferase was significantly correlated with an increase in α-fetoproteins (p = 0.01), and severe necro-inflammatory activity (p = 0.001). Associated comorbidities were found in 71.6%, mainly coronary artery and gastrointestinal disorders. The cumulative incidence in the region was 2.6 per 10,000 inhabitants. Our data highlight the role of reference hospitals in Brazil’s public health system in the treatment of HCV. Low incidence rates demonstrated the fragility of municipalities in the active search for patients.

Download Full-text

IMPROVEMENT OF LIVER STIFFNESS VALUES MEASURED BY TRANSITION ELASTOGRAPHY AFTER CHRONIC HEPATITIS C TREATMENT WITH DIRECT ACTION ANTIVIRALS AND EVOLUTIVE CORRELATION OF THROMBOCYTOPENIA AND PRESENCE OF ESOPHAGEAL VARICES

10.26226/morressier.59a6b346d462b80290b5497a ◽

2017 ◽

Author(s):

Miguel Perez Ferrer

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Esophageal Varices ◽

Direct Action ◽

Liver Stiffness ◽

Hepatitis C Treatment

Download Full-text

Stress stability study of simeprevir, a hepatitis C virus inhibitor, using feasible TLC-spectro-densitometry: application to pharmaceutical dosage form and human plasma

RSC Advances ◽

10.1039/d0ra01172j ◽

2020 ◽

Vol 10 (36) ◽

pp. 21100-21107 ◽

Cited By ~ 1

Author(s):

Bassam Shaaban Mohammed ◽

Amal E. Hamad ◽

Sayed M. Derayea

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Human Plasma ◽

Dosage Form ◽

Direct Action ◽

Stability Study ◽

Pharmaceutical Dosage Form ◽

Virus Inhibitor

Simeprevir is one of the newest direct action anti-hepatitis C drugs.

Download Full-text

New direct action antivirals containing regimes to treat patients with hepatitis C chronic infection: first results from a national real-world registry of the Brazilian Hepatology Society

Journal of Hepatology ◽

10.1016/s0168-8278(17)31417-4 ◽

2017 ◽

Vol 66 (1) ◽

pp. S508 ◽

Cited By ~ 2

Author(s):

H. Cheinquer H ◽

H.S. Coelho ◽

R.S. Aires ◽

E.D. Quintela ◽

C. Lobato ◽

...

Keyword(s):

Hepatitis C ◽

Real World ◽

Chronic Infection ◽

Direct Action ◽

First Results

Download Full-text

Considerations on Direct Antiviral Agent Therapy in Patients Having Chronic Hepatitis C from Constanta County

Acta Medica Marisiensis ◽

10.2478/amma-2014-0043 ◽

2014 ◽

Vol 60 (5) ◽

pp. 204-206 ◽

Cited By ~ 1

Author(s):

Angelica Stavar ◽

Irina-Magdalena Dumitru ◽

S Rugina

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Triple Therapy ◽

Chronic Hepatitis C ◽

Standard Therapy ◽

Adverse Reactions ◽

Standard Treatment ◽

Direct Action ◽

High Rate ◽

Number Of Patients

Abstract Introduction: Direct-acting antiviral agents (DAA) have a direct action in chronic hepatitis C, their addition to the standard therapy with interferon alfa2 (IFN) and ribavirin (RBV) significantly improving the sustained virologic response (SVR) in this disease. Objective: The study analyses the results of triple therapy inclduign DAA in terms of tolerability and efficiency. Material and method: We selected a lot of 24 patients who concluded the DAA administration period, being in the period of finalization of standard therapy at the time of the study. In all the patients clinical and paraclinical assesment was performed including laboratory tests, fibroscan, echography, etc. Results: The duration of the therapy consisting in association of DAA to the standard treatment was 3 months and led to a remarkable result represented by a high rate of negativation of viremia (83.3%). Among the adverse reactions recorded, the most important were: anemia 17 patients (70.8%), leucopenia 10 patients (41.6%), thrombocitopenia 14 patients (58.3%), hyperbilirubinemia 3 patients (12,5%); hyperuricemia 8 patients (33,3%), hypocalcemia 4 patients (16.6%), loss of weight 4 patients (16,6%), anal pruritus (16,6%); among the 24 patients, 2% did not exhibit any adverse reactions. Conclusions: Despite of the various adverse reactions recorded, the triple therapy consisting in DAA added to the standard treatment proves its utility, and the high rates of sustained viral reaction justifies its utilization. It is necessary to increase the number of patients who benefit from the advantages of triple therapy, which, after becoming larger available, could become a new standard therapy in patients with viral chronic hepatitis.

Download Full-text

IMMUNE STATUS IN HIV-INFECTED PATIENTS COINFECTED WITH HEPАTITIS C VIRUS (HCV)

HIV Infection and Immunosuppressive Disorders ◽

10.22328/2077-9828-2018-10-4-25-36 ◽

2019 ◽

Vol 10 (4) ◽

pp. 25-36

Author(s):

K. V. Shmagel ◽

V. A. Chereshnev

Keyword(s):

Hepatitis C ◽

Antiretroviral Therapy ◽

Hiv Infection ◽

Immune Status ◽

Direct Action ◽

Hcv Infection ◽

Viral Hepatitis C ◽

Negative Effect ◽

Negative Role

The most common co-infection associated with HIV infection is viral hepatitis C. More than half of HIV-infected patients is coinfected with HCV in Russia. Both infections can have a reciprocal negative effect, what is reflected in an increase in the morbidity and mortality of co-infected patients compared with mono-infected patients. The negative role of HIV infection in the development of hepatitis C is manifested by the acceleration of the process of fibrosis and the formation of cirrhosis of the liver, as well as the frequent occurrence of hepatocellular carcinoma. The effects of HCV infection on the course of HIV infection have been less studied. It is known that hepatitis can slow down the immune reconstitution while receiving antiretroviral therapy. In addition, a violation of the hepatic barrier for products supplying from the intestine, apparently, can lead to additional activation of the immune system, aggravatted immunodeficiency, increased systemic inflammation and the development of AIDS-non-associated diseases, primarily cardiovascular diseases. Most researchers see the solution of the problem in the early start of antiretroviral therapy, as well as in the transition from interferon therapy to the appointment of drugs of direct action in the treatment of HCV infection.

Download Full-text